LifeView
Preimplantation genetic testing for polygenic risk assessment
Company profile
Company profile
Genomic Prediction is a precision medicine company specializing in advanced genetic testing and polygenic risk assessment for reproductive health. The company develops and offers preimplantation genetic testing services that utilize polygenic risk scores to evaluate embryos during in vitro fertilization (IVF) procedures. Their technology analyzes multiple genetic variants simultaneously to assess risk for complex conditions and traits, going beyond traditional single-gene disorder screening. Genomic Prediction's services are designed to provide prospective parents and fertility clinics with comprehensive genetic information to support informed decision-making during the embryo selection process. The company operates at the intersection of genomics, artificial intelligence, and reproductive medicine, applying computational methods to interpret genetic data and predict health outcomes. Their approach represents an evolution in preimplantation genetic testing, incorporating polygenic risk assessment alongside traditional genetic screening methods to provide a more complete picture of embryo health potential.
Company description Genomic Prediction official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Other deployment with recorded integration context.
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Preimplantation genetic testing for polygenic risk assessment
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Nature communications · Jun 3, 2026
Accuracy of direct mutation testing by TaqMan quantitative polymerase chain reaction for preimplantation genetic diagnosis of recurrent de novo mutations.Fertility and sterility · Apr 1, 2026
Population-specific polygenic risk scores for people of Han Chinese ancestry.Nature · Dec 1, 2025
Blastocyst segmental aneuploidy breakpoints are highly correlated with human genome fragile sites.Human reproduction (Oxford, England) · Oct 1, 2025
Routine detection of consanguinity through preimplantation genetic testing in human embryos.Reproductive biomedicine online · May 1, 2025
Efficient blockLASSO for polygenic scores with applications to all of us and UK Biobank.BMC genomics · Mar 27, 2025
Clinical validation
NCT04167748 · Sponsor · RECRUITING
Follow-up With Preimplantation Genetic Testing PatientsNCT04477863 · Sponsor · RECRUITING
Embryo Health StudyNCT04528498 · Sponsor · RECRUITING
ANXA5 M2 Haplotyping in IVF Patients and EmbryosNCT04544462 · Sponsor · ACTIVE NOT RECRUITING
Cell Free Preimplantation Genetic TestingNCT04628507 · Sponsor · NOT YET RECRUITING
GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical TrialNCT06141135 · Sponsor · RECRUITING
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Genomic Prediction's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.